/

Società

Me

Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

196 comunicati stampa

Guarda tutti i comunicati

07/04/2026

Mercato del lavoro

Mercato azionario

Industria

Biotecnologia

Salute

Scienza

Farmaceutica

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Fonte

Merck & Co., Inc.

Emittente

1.00

0

02/04/2026

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Ottica

Biotecnologia

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

Fonte

Merck & Co., Inc.

Emittente

1.00

0

02/04/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

Fonte

Merck & Co., Inc.

Emittente

1.00

0

01/04/2026

Web e Social Network

Telefonia e Varie

Finanza

Mercato azionario

Biotecnologia

Farmaceutica

Salute

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

Fonte

Merck & Co., Inc.

Emittente

1.00

0

30/03/2026

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Fonte

Merck & Co., Inc.

Emittente

1.00

0

29/03/2026

Eventi

Fiere

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Cardiologia

Biotecnologia

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Fonte

Merck & Co., Inc.

Emittente

1.00

0

25/03/2026

Web e Social Network

Mercato azionario

Telefonia e Varie

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

18/03/2026

Industria

Igiene alimentare

Salute

Vetrine/Shopping

Animali

Farmaceutica

Veterinaria

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

Fonte

Merck & Co., Inc.

Emittente

1.00

0

16/03/2026

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Cardiologia

Biotecnologia

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

Fonte

Merck & Co., Inc.

Emittente

1.00

0

28/02/2026

Multimedialità

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0